WO2009129538A3 - Human equivalent monoclonal antibodies engineered from nonhuman variable regions - Google Patents

Human equivalent monoclonal antibodies engineered from nonhuman variable regions Download PDF

Info

Publication number
WO2009129538A3
WO2009129538A3 PCT/US2009/041144 US2009041144W WO2009129538A3 WO 2009129538 A3 WO2009129538 A3 WO 2009129538A3 US 2009041144 W US2009041144 W US 2009041144W WO 2009129538 A3 WO2009129538 A3 WO 2009129538A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibodies
variable regions
human equivalent
antibodies engineered
nonhuman variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/041144
Other languages
French (fr)
Other versions
WO2009129538A2 (en
Inventor
Matthew J. Bernett
Gregory Moore
John R. Desjarlais
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xencor Inc
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor Inc filed Critical Xencor Inc
Priority to EP09733117A priority Critical patent/EP2280997A2/en
Publication of WO2009129538A2 publication Critical patent/WO2009129538A2/en
Publication of WO2009129538A3 publication Critical patent/WO2009129538A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention is directed to the creation of human equivalent CDRs and antibodies containing them by a method of producing an antibody which specifically binds to an antigen.
PCT/US2009/041144 2008-04-18 2009-04-20 Human equivalent monoclonal antibodies engineered from nonhuman variable regions Ceased WO2009129538A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09733117A EP2280997A2 (en) 2008-04-18 2009-04-20 Human equivalent monoclonal antibodies engineered from nonhuman variable regions

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US4639908P 2008-04-18 2008-04-18
US61/046,399 2008-04-18
US11544908P 2008-11-17 2008-11-17
US61/115,449 2008-11-17
US12067508P 2008-12-08 2008-12-08
US61/120,675 2008-12-08

Publications (2)

Publication Number Publication Date
WO2009129538A2 WO2009129538A2 (en) 2009-10-22
WO2009129538A3 true WO2009129538A3 (en) 2010-07-01

Family

ID=41199792

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/041144 Ceased WO2009129538A2 (en) 2008-04-18 2009-04-20 Human equivalent monoclonal antibodies engineered from nonhuman variable regions

Country Status (3)

Country Link
US (1) US8314213B2 (en)
EP (1) EP2280997A2 (en)
WO (1) WO2009129538A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105121470A (en) * 2013-03-15 2015-12-02 艾伯维生物技术有限公司 Anti-CD25 antibody and use thereof
US11566080B2 (en) 2008-09-17 2023-01-31 Xencor, Inc. Compositions and methods for treating IgE-mediated disorders

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051438A2 (en) 2000-12-22 2002-07-04 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (rgm) and its modulators
EP1928905B1 (en) * 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
EP2033971A1 (en) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP) binding domains of proteins of the Repulsive Guidance Molecule (RGM) protein family and functional fragments thereof and their application
US8962803B2 (en) * 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
KR20110138412A (en) * 2009-04-16 2011-12-27 애보트 바이오테라퓨틱스 코포레이션 Anti-ΤΝF-α Antibodies and Uses thereof
ES2534355T3 (en) * 2009-06-17 2015-04-21 Abbvie Biotherapeutics Inc. Anti-VEGF antibodies and their uses
BR112012013734A2 (en) * 2009-12-08 2017-01-10 Abbott Gmbh & Co Kg monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration.
WO2011159704A1 (en) * 2010-06-14 2011-12-22 Vaccinex, Inc. Anti-vegf antibodies and uses thereof
EP3741883B1 (en) * 2010-07-16 2022-12-14 Adimab, LLC Antibody libraries
WO2012031273A2 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
MX349057B (en) 2010-11-30 2017-07-07 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT THAT INDUCES CYTOTOXICITY.
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
WO2013092998A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of antibodies
RS57603B1 (en) 2012-01-27 2018-11-30 Abbvie Deutschland Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
KR102129636B1 (en) * 2012-05-31 2020-07-03 제넨테크, 인크. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
EP2872894B1 (en) 2012-07-13 2019-04-17 Innate Pharma Screening of conjugated antibodies
KR102134088B1 (en) 2012-08-24 2020-07-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
ES2660029T3 (en) * 2012-10-12 2018-03-20 Medimmune Limited Antibody-pyrrolobenzodiazepine conjugates
WO2014072482A1 (en) 2012-11-09 2014-05-15 Innate Pharma Recognition tags for tgase-mediated conjugation
US20140154255A1 (en) * 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
LT2943511T (en) 2013-01-14 2019-11-11 Xencor Inc Novel heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
HRP20211353T1 (en) 2013-02-07 2021-11-26 The General Hospital Corporation PROCEDURES FOR EXPANSION OR DEPLETATION OF REGULATORY T-STATIONS
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
EP2968582B1 (en) 2013-03-15 2020-07-01 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10544187B2 (en) 2013-03-15 2020-01-28 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
HK1220470A1 (en) * 2013-03-15 2017-05-05 Abbvie Biotechnology Ltd. Anti-cd25 antibodies and their uses
EP3010547B1 (en) 2013-06-20 2021-04-21 Innate Pharma Enzymatic conjugation of polypeptides
EP3010548A1 (en) 2013-06-21 2016-04-27 Innate Pharma Enzymatic conjugation of polypeptides
AU2015237184B2 (en) 2014-03-28 2020-11-26 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
CA2945485A1 (en) * 2014-04-16 2015-10-22 Sorrento Therapeutics Inc. Antibody therapeutics that bind cd147
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
MD20160130A2 (en) 2014-04-27 2017-04-30 Ccam Biotherapeutics Ltd. Humanized antibodies against CEACAM1
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
KR102689285B1 (en) 2014-11-26 2024-07-31 젠코어 인코포레이티드 Heterodimeric antibodies that bind cd3 and tumor antigens
MA41019A (en) 2014-11-26 2021-05-05 Xencor Inc HETERODIMERIC ANTIBODIES BINDING TO CD3 AND CD38 ANTIGENS
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
US10947305B2 (en) 2015-03-20 2021-03-16 Full Spectrum Genetics, Inc. Anti-TNFα binding compounds and uses thereof
US10906982B2 (en) 2015-05-15 2021-02-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor 2 antibodies
EP3340999A4 (en) 2015-08-28 2019-06-12 The General Hospital Corporation TYPE II ANTI-RECEPTOR AGONISTIC ANTIBODIES OF TUMOR NECROSIS FACTOR
WO2017100372A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
CA3023930C (en) 2016-05-13 2025-09-23 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
KR102838691B1 (en) 2016-06-14 2025-07-25 젠코어 인코포레이티드 Bispecific checkpoint inhibitor antibodies
US10688181B2 (en) 2016-06-27 2020-06-23 The Regents Of The University Of California Cancer treatment combinations
CN116063545A (en) 2016-06-28 2023-05-05 Xencor股份有限公司 Heterodimeric antibody that binds to somatostatin receptor 2
CN107663240B (en) * 2016-07-29 2021-01-12 中国人民解放军第四军医大学 Single-chain antibody specifically bound by highly glycosylated CEA and application thereof in detection and treatment
US10550185B2 (en) 2016-10-14 2020-02-04 Xencor, Inc. Bispecific heterodimeric fusion proteins containing IL-15-IL-15Rα Fc-fusion proteins and PD-1 antibody fragments
CN110121505B (en) 2016-12-28 2023-08-01 株式会社绿十字细胞治疗 Chimeric antigen receptors and natural killer cells expressing them
JP2020529832A (en) 2017-06-30 2020-10-15 ゼンコア インコーポレイテッド Targeted heterodimer Fc fusion protein containing IL-15 / IL-15Rα and antigen binding domain
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
EP3712178A4 (en) 2017-11-14 2021-08-11 Green Cross Lab Cell Corporation ANTI-HER2 ANTIBODIES OR ANTIGEN BINDING FRAGMENT OF THE SAME, AND CHEMERICAL ANTIGENIC RECEPTOR INCLUDING IT
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
IL275426B2 (en) 2017-12-19 2025-03-01 Xencor Inc Engineered FC fusion proteins containing IL-2
EP3773911A2 (en) 2018-04-04 2021-02-17 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
WO2019204665A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
US11505595B2 (en) 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
JP7612571B2 (en) 2018-10-03 2025-01-14 ゼンコア インコーポレイテッド IL-12 heterodimer FC-fusion protein
JP7652690B2 (en) 2018-11-15 2025-03-27 ザ ジェネラル ホスピタル コーポレイション Agonistic tumor necrosis factor receptor superfamily polypeptides
CA3121168A1 (en) * 2018-11-30 2020-06-04 Memorial Sloan Kettering Cancer Center Heterodimeric tetravalency and specificity antibody compositions and uses thereof
BR112021016955A2 (en) 2019-03-01 2021-11-23 Xencor Inc Composition, nucleic acid composition, expression vector composition, expression vector, host cell, methods of producing an ectonucleotide pyrophosphatase/phosphodiesterase family 3 member binding domain and of treating a cancer, anti-enpp3 antibody , and, heterodimeric antibody
WO2020200944A1 (en) * 2019-03-29 2020-10-08 F. Hoffmann-La Roche Ag Method for generating avid-binding multispecific antibodies
AU2019464494A1 (en) * 2019-09-03 2022-04-14 OncoTab, Inc. Tumor specific antibody conjugates and uses therefor
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
CN113759121A (en) * 2020-06-05 2021-12-07 首都医科大学附属北京世纪坛医院 Application of urinary immunoglobulin κ variable region 3D-7 and its polypeptide fragments in burns
KR102784691B1 (en) * 2020-08-11 2025-03-25 주식회사 카나프테라퓨틱스 Fusion protein comprising il-12 and anti-cd20 antibody and use thereof
KR20230166150A (en) 2020-08-19 2023-12-06 젠코어 인코포레이티드 Anti-cd28 compositions
JP2024511319A (en) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Heterodimeric antibody that binds to CD3 and CLDN6
JP2024509274A (en) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Heterodimeric antibody that binds to CD3 and GPC3
EP4547698A1 (en) 2022-07-01 2025-05-07 Neurogene Inc. Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003025019A1 (en) * 2001-09-20 2003-03-27 Alexion Pharmaceuticals, Inc. Anti-pdgf antibodies and methods for producing engineered antibodies
WO2003050260A2 (en) * 2001-12-07 2003-06-19 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
WO2005014653A2 (en) * 2003-02-28 2005-02-17 Protein Design Labs, Inc. Humanized chicken antibodies
WO2005054273A2 (en) * 2003-11-26 2005-06-16 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
WO2005056759A2 (en) * 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2005079479A2 (en) * 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
WO2006020114A2 (en) * 2004-08-04 2006-02-23 Applied Molecular Evolution, Inc. Variant fc regions
WO2006105338A2 (en) * 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
WO2006135793A2 (en) * 2005-06-09 2006-12-21 Xencor, Inc. Protein engineering with analogous contact environments
US7297334B2 (en) * 1997-04-07 2007-11-20 Genentech, Inc. Anti-vegf antibodies
WO2008031056A2 (en) * 2006-09-08 2008-03-13 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6797492B2 (en) * 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
AU2002248184C1 (en) * 2000-12-12 2018-01-04 Board Of Regents, The University Of Texas System Molecules with extended half-lives, compositions and uses thereof
US7117096B2 (en) * 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US8188231B2 (en) * 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US8084582B2 (en) * 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20070275460A1 (en) * 2003-03-03 2007-11-29 Xencor.Inc. Fc Variants With Optimized Fc Receptor Binding Properties
US7226231B2 (en) 2003-07-17 2007-06-05 Medical Instill Technologies, Inc. Piston-type dispenser with one-way valve for storing and dispensing metered amounts of substances
JP2007531707A (en) * 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド Modification of Fc fusion protein serum half-life by mutagenesis of heavy chain constant region positions 250, 314 and / or 428 of IG
JP2008504002A (en) 2003-11-12 2008-02-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド Neonatal Fc receptor (FcRn) binding polypeptide variants, dimeric Fc binding proteins, and methods related thereto
CA2624189A1 (en) * 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297334B2 (en) * 1997-04-07 2007-11-20 Genentech, Inc. Anti-vegf antibodies
WO2003025019A1 (en) * 2001-09-20 2003-03-27 Alexion Pharmaceuticals, Inc. Anti-pdgf antibodies and methods for producing engineered antibodies
WO2003050260A2 (en) * 2001-12-07 2003-06-19 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
WO2005014653A2 (en) * 2003-02-28 2005-02-17 Protein Design Labs, Inc. Humanized chicken antibodies
WO2005054273A2 (en) * 2003-11-26 2005-06-16 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
WO2005056759A2 (en) * 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2005079479A2 (en) * 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
WO2006020114A2 (en) * 2004-08-04 2006-02-23 Applied Molecular Evolution, Inc. Variant fc regions
WO2006105338A2 (en) * 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
WO2006135793A2 (en) * 2005-06-09 2006-12-21 Xencor, Inc. Protein engineering with analogous contact environments
WO2008031056A2 (en) * 2006-09-08 2008-03-13 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DAVIES J ET AL: "Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 2, no. 3, 1 September 1996 (1996-09-01), pages 169 - 179, XP004070292, ISSN: 1380-2933 *
HOLT L J ET AL: "Domain antibodies: proteins for therapy", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 11, 1 November 2003 (2003-11-01), pages 484 - 490, XP004467495, ISSN: 0167-7799 *
LAZAR ET AL: "A molecular immunology approach to antibody humanization and functional optimization", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 44, no. 8, 1 December 2006 (2006-12-01), pages 1986 - 1998, XP005792736, ISSN: 0161-5890 *
PRESTA L G ET AL: "HUMANIZATION OF AN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOCLONAL ANTIBODY FOR THE THERAPY OF SOLID TUMORS AND OTHER DISORDERS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, vol. 57, 15 October 1997 (1997-10-15), pages 4593 - 4599, XP002926854, ISSN: 0008-5472 *
QUEEN C ET AL: "A HUMANIZED ANTIBODY THAT BINDS TO THE INTERLEUKIN 2 RECEPTOR", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. (PNAS), NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 86, 1 December 1989 (1989-12-01), pages 10029 - 10033, XP002947922, ISSN: 0027-8424 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11566080B2 (en) 2008-09-17 2023-01-31 Xencor, Inc. Compositions and methods for treating IgE-mediated disorders
US12559572B2 (en) 2008-09-17 2026-02-24 Xencor, Inc. Compositions and methods for treating IgE-mediated disorders
CN105121470A (en) * 2013-03-15 2015-12-02 艾伯维生物技术有限公司 Anti-CD25 antibody and use thereof

Also Published As

Publication number Publication date
US20100004431A1 (en) 2010-01-07
US8314213B2 (en) 2012-11-20
EP2280997A2 (en) 2011-02-09
WO2009129538A2 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
WO2009129538A3 (en) Human equivalent monoclonal antibodies engineered from nonhuman variable regions
WO2013037484A3 (en) Anti-aplhabetatcr antibody
IL202232A (en) Method for producing humanized antibody derived from parent rabbit antibody that binds to desired antigen and humanized antibody or antibody fragment produced by said method
NZ712765A (en) Antibodies that bind csf1r
NZ598202A (en) High affinity human antibodies to human angiopoietin-2
NZ703035A (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
CR20110577A (en) IL-1 UNION PROTEINS
WO2008006235A3 (en) Scfv antibodies which pass epithelial and/or endothelial layers
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
WO2013054331A8 (en) Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
NZ595464A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
WO2010027488A3 (en) Monoclonal antibodies
NZ618067A (en) Anti-cd100 antibodies and methods for using the same
NZ608033A (en) Anti-ox40 antibodies and methods of using the same
NZ611269A (en) Neutralizing anti-ccl20 antibodies
WO2007115049A3 (en) Humanized monoclonal antibodies to hepatocyte growth factor
WO2009120927A3 (en) Methods of treatment
NZ600262A (en) Anti-her3 antibodies and uses thereof
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
WO2008097817A3 (en) Multivariable antigens complexed with targeting humanized monoclonal antibody
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
RU2531523C3 (en) STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF
WO2010046775A3 (en) Methods for producing antibodies from plasma cells
NZ623807A (en) Antibodies that bind human cd27 and uses thereof
WO2009071696A3 (en) Humanized antibody molecules specific for il-31

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09733117

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009733117

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE